Related Experiment Video

Updated: Sep 15, 2025

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

1.2K

DEK facilitates bortezomib resistance of multiple myeloma by modulating ferroptosis

Huiquan Wang1, Jiafeng Zhang1, Lei Chen1

  • 1Department of Laboratory Medicine, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.

Clinical and Experimental Medicine
|July 17, 2025
PubMed

Insights

DEK oncogene (DEK) drives bortezomib resistance in multiple myeloma (MM) by promoting cancer cell survival. Depleting DEK sensitizes MM cells to bortezomib by inducing ferroptosis, offering new therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Multiple myeloma (MM) is a prevalent blood cancer.
  • Resistance to proteasome inhibitors like bortezomib (BTZ) is a major challenge in MM treatment.
  • The underlying mechanisms of BTZ resistance are not fully understood.

Purpose of the Study:

  • To identify key genes and mechanisms contributing to BTZ resistance in MM.
  • To investigate the role of the DEK oncogene (DEK) in MM drug resistance.

Main Methods:

  • Bioinformatic analysis of differentially expressed genes in MM.
  • Experimental validation in BTZ-resistant MM cell lines.
  • Gene depletion studies and ferroptosis induction assays.

Main Results:

  • DEK was identified as a critical gene associated with BTZ resistance in MM.
  • DEK was overexpressed in MM patients and BTZ-resistant cell lines.
  • DEK depletion sensitized MM cells to bortezomib by inducing ferroptosis.

Conclusions:

  • DEK plays a significant role in mediating bortezomib resistance in multiple myeloma.
  • Targeting DEK may represent a novel therapeutic strategy for overcoming BTZ resistance in MM.
  • The induction of ferroptosis by DEK depletion offers a new mechanism for MM treatment.
Keywords:
Hematological diseaseMultiple myelomadrug resistanceferroptosis

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.4K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K

Related Concept Videos

Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.1K